


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Silence et al.
Serial No.: 10/534,348
Confirmation No.: 4929
Filed: May 9, 2005
For: SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST
TUMOR NECROSIS FACTOR ALPHA AND USES
THEREFOR
Examiner: Gregory S. Emch
Art Unit: 1649

Certificate of Electronic Filing Under 37 CFR 1.8

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: February 8, 2011


Eileen M. Flaherty

STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

The Applicant would like to bring to the Examiner's attention the following search reports or other communications from corresponding or related applications.

<u>Serial No.</u>	<u>Mailing Date</u>	<u>Type(s) of Communication</u>
EP 03447005.4	August 19, 2003	Partial European Search Report
EP 07014054.6	March 7, 2008	Partial European Search Report
PCT/BE03/00190	July 1, 2004	International Search Report
PCT/BE2003/00189	July 16, 2004	International Search Report
PCT/BE2003/00189	March 30, 2006	International Preliminary Examination Report
PCT/BE2003/00189	August 31, 2005	Written Opinion
PCT/BE2003/00190	February 22, 2005	International Preliminary Examination Report
PCT/BE/2003/00190	December 20, 2004	Written Opinion
PCT/BE2003/00192	May 14, 2004	International Search Report
PCT/BE2003/00192	July 20, 2004	Written Opinion
PCT/BE2003/00192	November 23, 2004	International Preliminary Examination Report
PCT/BE03/00193	July 15, 2004	International Search Report
PCT/BE/03/00193	March 22, 2005	International Preliminary Examination Report
PCT/BE03/00193	November 12, 2004	Written Opinion
PCT/BE03/00194	January 12, 2005	International Preliminary Examination Report
PCT/BE03/00194	July 15, 2004	International Search Report
PCT/BE03/00194	September 6, 2004	Written Opinion
JP 2005-502086	February 8, 2010	Examination Report

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

The Director is hereby authorized to charge any deficiency or credit any overpayment in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 23/2825.

Respectfully submitted,

By: 

Erik J. Spek, Ph.D., Reg. No. 61,065
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: A0848.70005US00
Date: February 8, 2011
xNDDx